Aciraft-LS Capsules

Product Description

Aciraft-LS combines an acid-suppressing proton pump inhibitor with a prokinetic component. Rabeprazole reduces gastric acid secretion, while levosulpiride is used to support gastric motility in selected acid-related disorders.

The enteric-coated and sustained-release pellet system is intended to provide site-appropriate release and prolonged action. It may be prescribed for GERD with dyspeptic symptoms, reflux associated with delayed gastric emptying and related conditions.

Composition / Nutritional Information

• Rabeprazole Sodium IP — 20 mg (enteric-coated pellets)
• Levosulpiride IP — 75 mg (sustained-release pellets)
• Excipients — q.s.

Indications / Intended Support

• GERD with dyspeptic symptoms
• Functional dyspepsia
• Acid reflux with bloating or nausea
• Delayed gastric emptying associated symptoms

Key Product Features

• Combines acid suppression with prokinetic support
• Sustained-release component
• May support relief of reflux and dyspeptic symptoms
• Designed for physician-supervised gastrointestinal therapy